Dr. Ghobrial is the Senior Vice President for Experimental Medicine, Director of the Center for Early Detection and Interception of Blood Cancers, Director of the Ghobrial Lab, Co-Leader of the Lymphoma/Myeloma Cancer Center Program, and Professor of Medicine at Dana-Farber Cancer Institute and Harvard Medical School.
Dr. Ghobrial is a physician-scientist who specializes in multiple myeloma (MM) and Waldenström macroglobulinemia (WM), specifically in the precursor conditions of monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma.
Her research focuses on precursor conditions of multiple myeloma, aiming to understand genetic, epigenetic, and immune mechanisms of disease progression, identify novel biomarkers, and develop therapies to eliminate disease before progression. In addition, her laboratory research data has been rapidly translated to innovative, investigator-initiated clinical trials. She has led 15+ clinical trials in Waldenstrom macroglobulinemia and multiple myeloma precursor conditions. She developed the PCROWD Study, a large, patient-empowering observational study for these precursor conditions, and the PROMISE Study, which screens high-risk individuals, including those of African descent or with a family history of blood cancer.